Literature DB >> 31129645

Chondrosarcoma presenting as a rare primary malignant tumour of the chest wall.

Calvin Abro1, Khader Herzallah2, Fawzi Abu Rous1, Yehia Saleh1.   

Abstract

Entities:  

Keywords:  cancer intervention; cancer–see oncology; cardiovascular medicine; oncology

Mesh:

Substances:

Year:  2019        PMID: 31129645      PMCID: PMC6536220          DOI: 10.1136/bcr-2019-230104

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


× No keyword cloud information.
  5 in total

Review 1.  Chondroma and chondrosarcoma.

Authors:  J Somers; L P Faber
Journal:  Semin Thorac Cardiovasc Surg       Date:  1999-07

2.  Primary chest wall tumors: early and long-term results of surgical treatment.

Authors:  K Athanassiadi; G Kalavrouziotis; D Rondogianni; A Loutsidis; A Hatzimichalis; I Bellenis
Journal:  Eur J Cardiothorac Surg       Date:  2001-05       Impact factor: 4.191

3.  Predictors of survival in malignant tumors of the sternum.

Authors:  N Martini; A G Huvos; M E Burt; R T Heelan; M S Bains; P M McCormack; V W Rusch; M Weber; R J Downey; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  1996-01       Impact factor: 5.209

4.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Authors:  Hussein A Tawbi; Melissa Burgess; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; James Hu; Sandra D'Angelo; Steven Attia; Richard F Riedel; Dennis A Priebat; Sujana Movva; Lara E Davis; Scott H Okuno; Damon R Reed; John Crowley; Lisa H Butterfield; Ruth Salazar; Jaime Rodriguez-Canales; Alexander J Lazar; Ignacio I Wistuba; Laurence H Baker; Robert G Maki; Denise Reinke; Shreyaskumar Patel
Journal:  Lancet Oncol       Date:  2017-10-04       Impact factor: 41.316

5.  Surgically-challenging chondrosarcomas of the chest wall: five-year follow-up at a single institution.

Authors:  Daniel Reis Waisberg; Fernando Conrado Abrão; Angelo Fernandez; Ricardo Mingarini Terra; Paulo Manuel Pêgo-Fernandes; Fabio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.